Article thumbnail

Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial

By Kang Hyun Choi, Woo Chul Chung, Kang-Moon Lee, Chang Nyol Paik, Eun Jung Kim, Bong Koo Kang, Ju Hyun Oak and Sung Hoon Jung


The aim of this study was to evaluate the efficacy of levofloxacin and rifaximin based quadruple regimen as first-line treatment for Helicobacter pylori infection. A prospectively randomized, double-blinded, parallel group, comparative study was performed. Three hundred consecutive H. pylori positive patients were randomized to receive: omeprazole, amoxicillin, clarithromycin (OAC); omeprazole, amoxicillin, levofloxacin (OAL); and omeprazole, amoxicillin, levofloxacin, rifaximin (OAL-R). The eradication rates in the intention to treat (ITT) and per protocol (PP) analyses were: OAC, 77.8% and 85.6%; OAL, 65.3% and 73.6%; and OAL-R, 74.5% and 80.2%. The eradication rate achieved with OAC was higher than with OAL on the ITT (P = 0.05) and PP analysis (P = 0.04). OAL-R regimen was not inferior to OAC. The frequency of moderate to severe adverse effects was significantly higher in OAC treatment group. Especially, diarrhea was most common complaint, and there was a significantly low rate of moderate to severe diarrhea with the rifaximin containing regimen. In conclusion, the levofloxacin and rifaximin based regimen comes up to the standard triple therapy, but has a limited efficacy in a Korean cohort. The rifaximin containing regimen has a very high safety profile for H. pylori eradication therapy

Topics: Original Article
Publisher: The Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther
  2. (2010). Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump iInhibitor, amoxicillin and clarithromycin.
  3. (2003). Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases.
  4. (2007). Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease.
  5. (2003). Clarithromycin resistance among Helicobacter pylori strains isolated from children: Prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis.
  6. (1996). Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro.
  7. (2006). Clinical usefulness of antimicrobial susceptibility test for Helicobacter pylori.
  8. (2006). Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients.
  9. (2007). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut
  10. (1997). Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG).
  11. (1992). Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, coltrolled study. Ann Intern Med
  12. (2010). Efficacy and safety of levofloxacin, clarithromycin and esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
  13. (2004). Evaluation of Helicobacter pylori susceptibility to rifaximin. Gastroenterol Hepatol
  14. (2002). Factors associated with treatment failure of Helicobacter pylori infection in a developing country.
  15. (2010). Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut
  16. (2001). Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’ . Aliment Pharmacol Ther
  17. (2004). pylori antimicrobial resistance: prevalence, importance, and advances in testing. Gut
  18. (2009). pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
  19. (2003). Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther
  20. (2005). Rifaximin – a novel antimicrobial for enteric infections.
  21. (2006). Rifaximin-based regimens for eradication of Helicobacter pylori: a pi-Choi KH, et al. • Levofloxacin and Rifaximin Based Quadruple Therapy 790 DOI: 10.3346/jkms.2011.26.6.785 lot study. Dig Dis
  22. (2000). Strategies to treat patients with antibiotic resistant Helicobacter pylori.
  23. (2002). Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori.
  24. (2006). The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication.
  25. (1999). The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis.
  26. (1999). The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology
  27. (2002). Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther